Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEVENTY: CD70 CAR T-cell Therapy for Relapsed/Refractory Leukemia
NCT06345027Phase 1Recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Apr 2026
- Primary completion
- Jun 2029
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C7R-Epstein-Barr virus-specific T cells in acute myeloid leukemia (AML), B-cell leukemia (BCL) and T-cell leukemia, sponsored by Baylor College of Medicine. Primary endpoint: Dose Limiting Toxicity Rate at 4 weeks. Started Apr 2026; status: recruiting.
02
Drugs
C7R-Epstein-Barr virus-specific T cells
03
Conditions
acute myeloid leukemia (AML)B-cell leukemia (BCL)T-cell leukemia
Beyond the preview
Go deeper on NCT06345027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06345027.